Metraipolis › archive › dc_34795ae4744a
Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer — Europe PMC PMID:42398129
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42398129
- DOI
- 10.1016/j.breast.2026.104853
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T14:22:13.923Z
- SHA-256 of the archived text
efb25ee4fa52b8f8a574c2ab9094751d838ee5d44624d4e5cb5ba657f563edc6- Stable URL of this page
https://metraipolis.com/documento/dc_34795ae4744a
How to cite
Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer — Europe PMC PMID:42398129 — Europe PMC (en), https://europepmc.org/article/MED/42398129 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_34795ae4744a (Metraipolis archive dc_34795ae4744a, sha256 efb25ee4fa52b8f8a574c2ab9094751d838ee5d44624d4e5cb5ba657f563edc6)
BibTeX
@misc{dc34795ae4744a,
title = {Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer — Europe PMC PMID:42398129},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42398129},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_34795ae4744a; sha256 efb25ee4fa52b8f8a574c2ab9094751d838ee5d44624d4e5cb5ba657f563edc6},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42398129. Agents can read the archived copy with the MCP tool read_document.